“…With prices exceeding $100 million per unit, the cost-benefit ratio remains to be accurately described; efficacy data are still maturing. Diseases for which benefits have been seen with charged particles include uveal melanomas, 51 optic pathway gliomas, 52 skull-based tumors, 53 pituitary adenomas, 54 acoustic neuromas, 55 nasopharynx and paranasal sinuses, 56,57 spinal cord tumors, 58,59 prostate cancer, 60,61 lung cancer, [62][63][64][65] gastrointestinal malignancies, [66][67][68] and pediatric cancers. 69 …”